PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2002
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC151148/
https://ncbi.nlm.nih.gov/pubmed/12370270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI15634
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars